ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

クロロトリアニセン

Chlorotrianisene

HCID 11289
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
569-57-3
標準SMILES
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
InChIKey
BFPSDSIWYFKGBC-UHFFFAOYSA-N
分子式
C23H21ClO3
平均分子量
380.9 g/mol
単同位体質量
380.1179222

概要

Chlorotrianisene can cause cancer according to state or federal government labeling requirements.

名称と識別子

優先名称
Chlorotrianisene
IUPAC
1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
現地名
クロロトリアニセン
英語名
Chlorotrianisene
分子式
C23H21ClO3
分子量
380.86

名称と別名

chlorotrianisene569-57-3ChlortrianizenChlortrianisestrolChlortrianisenTACEChlorotrianisineChlorestroloChlorotrianizenChloortrianisestrolKhlortrianizenClorotrisin
名称をさらに表示
1-クロロ-1,2,2-トリス(4-メトキシフェニル)エテン1,1',1''-(1-クロロ-1,2,2-エテントリイル)トリス[4-メトキシベンゼン]クロロトリアニセンクロロトリアニセン‐D91-[1-クロロ-2,2-ビス(4-メトキシフェニル)エテニル]-4-メトキシベンゼン1,1′,1′′-(1-クロロ-1,2,2-エテントリイル)トリス[4-メトキシベンゼン]クロロトリアニセン-d9Chlorotrianisene (1 g)CSVPADA17NISBDCD156bNISBD1ADAM 17
HormoniseneClorestroloMerbentulAniseneMetaceRianilChlortrianisoestrolumChlorotrisin

データベース識別子

CAS
569-57-3
PubChem CID
11289
DTXSID
DTXSID1021299
ChEMBL
CHEMBL1200761

物性

構造計算による物性補完中

XLogP
6.4
極性表面積
27.7 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
6
重原子数
27
形式電荷
0
複雑度
442

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP6.4
OdorODORLESS
Color/Form · 2 件

CRYSTALS FROM METHANOL

SMALL WHITE CRYSTALS, OR AS CRYSTALLINE POWDER; EXHIBITS POLYMORPHISM

Solubility · 4 件

less than 0.1 mg/mL at 66 °F (NTP, 1992)

PRACTICALLY INSOL IN WATER; SOL IN ALCOHOL 0.28 G/100 ML; IN ETHER 3.6 G/100 ML; SOL IN GLACIAL ACETIC ACID, CARBON TETRACHLORIDE, VEGETABLE OILS

1 G SOL IN 360 ML OF METHANOL, 7 ML ACETONE, 2.5 ML BENZENE, IN ABOUT 1.5 ML CHLOROFORM; PRACTICALLY INSOL IN 2,2,4-TRIMETHYLPENTANE

1.99e-04 g/L

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 4 件

237 to 241 °F (NTP, 1992)

113-114

114-116 °C

115 °C

Physical Description · 2 件

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Regulatory InformationHazard Traits - Carcinogenicity
Other Safety InformationIMAP assessments - Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy-: Environment tier I assessment
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: When ingested, this compound can cause headache, nausea, vomiting, gynecomastia and sometimes vaginal bleeding.
Reactive GroupEthers
Reactivity Profile · 1 件

CHLOROTRIANISENE may react vigorously with strong oxidizing agents. Can react exothermically with reducing agents (such as alkali metals and hydrides) to release gaseous hydrogen. May react exothermically with both acids and bases. Various catalysts (such as acids) or initiators can cause very exothermic addition polymerization reactions.

Air and Water ReactionsSensitive to prolonged exposure to air and light. Insoluble in water.

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

化学と産業

薬理情報

ATC Code · 2 件

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein Binding50-80%
Pharmacodynamics · 1 件

Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.

Mechanism of Action · 1 件

Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

Metabolism/Metabolites · 2 件

Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
ChEBI
CHEBI:3641
UNII
6V5034L121
EC Number
209-318-6
Nikkaji
J6.531E

Small white crystals or white powder. Softens at 226 °F. Odorless. (NTP, 1992)

Solid

Stability/Shelf LifeSTABLE IN AIR
Other Experimental Properties · 2 件

SOFTENS AT 108 °C

ONE FORM MELTING @ ABOUT 116 °C & OTHER @ ABOUT 118 °C

物理化学的性質

融点
114 · 114-116°
沸点
496.07 °C · 496.07°C (rough estimate)
比重(密度)
1.101 · 1.1010 (rough estimate)
屈折率
1.4585 · 1.4585 (estimate)
貯蔵温度
-20 °C · Inert atmosphere,Store in freezer, under -20°C
溶解性
2 O; · insoluble in H2O; insoluble in EtOH; ≥16.1 mg/mL in DMSO
外見
solid
色
Off-white to light yellow
由来生物
rabbit
EPAの化学物質情報
Chlorotrianisene (569-57-3)
Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Interactions · 2 件

RELATED, NONESTROGENIC COMPD ETHAMOXYTRIPHETOL WAS FOUND TO BE STRIKINGLY ANTIESTROGENIC. IT INHIBITED...ESTROGEN GIVEN IN FORM OF NATURAL COMPD...CHLOROTRIANISENE.

ESTRADIOL NORMALLY CAUSES PRONOUNCED ENLARGEMENT OF PITUITARY, BUT WHEN CHLOROTRIANISENE WAS GIVEN CONCURRENTLY EFFECT WAS GREATLY REDUCED.

Human Toxicity Excerpts · 3 件

NEUROOPHTHALMIC LESIONS DURING ESTROGEN TREATMENT HAVE BEEN DESCRIBED. HYPERCALCEMIA MAY OCCUR, ESP IN MEN TAKING LARGE DOSES FOR PROSTATIC CARCINOMA. ALLERGIC REACTIONS INCL RASHES, ERYTHEMA MULTIFORME, ERYTHEMA NODOSUM, & CHOLESTATIC JAUNDICE. /ESTROGENS/

LEVEL OF ANTITHROMBIN III REMAINED AT DEPRESSED LEVEL IN WOMEN GIVEN 72 MG CHLOROTRIANISENE (TACE) ORALLY EVERY 12 HR FOR 4 DOSES. DEPRESSED LEVELS OF ANTITHROMBIN III MAY BE RISK FACTOR IN DEVELOPING THROMBOEMBOLISM.

SYNTHETIC NON-STEROIDAL ESTROGENS INCL...CHLOROTRIANISENE... ALTHOUGH LITTLE INFORMATION APPEARS TO BE AVAIL, THESE COMPD MUST HAVE VERY LOW SINGLE DOSE TOXICITY.

Non-Human Toxicity Excerpts · 1 件

Chlorotrianisene (CT) was evaluated for mutagenicity in the Salmonella/microsome preincubation assay using a standard protocol approved by the National Toxicology Program. CT was tested at doses of 0, 67, 100, 167, 333, 667, 1000, 1667, 3333, and 10,000 ug/plate in four Salmonella typhimurium strains (TA98, TA100, TA1535, and TA1537) in the presence and absence of Aroclor-induced rat or hamster liver S9. CT was negative in these tests and the highest ineffective dose level tested without formation of a precipitate in any Salmonella tester strain was 333 ug/plate.

安全データ

wgk
3
rtecs
KV0600000
ストレージクラス
10 - Combustible liquids
有毒物質データの
569-57-3(Hazardous Substances Data)

RATE OF O-DEMETHYLATION WAS MAXIMAL AT 0.4 MMOLAR NADPH. ALTHOUGH NADH DID NOT CATALYZE REACTION ALONE, IT HAD SYNERGISTIC EFFECT IN PRESENCE OF EQUIMOLAR AMT OF NADPH. EXTRACTS FROM INCUBATION MIXT CONTAINED 1 MAJOR (MONO-O-DEMETHYLATED) & A MINOR (BIS-O-DEMETHYLATED) METAB.

MeSH Pharmacological Classification · 2 件

Non-steroidal compounds with estrogenic activity.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Absorption, Distribution and Excretion · 4 件

Absorption following oral administration is rapid.

...LONG-ACTING...BECAUSE OF SEQUESTRATION IN ADIPOSE TISSUE &, THEREFORE, IS NOT WIDELY USED.

...SUGGESTS THAT DRUG IS CONVERTED IN LIVER TO MORE ACTIVE FORM. ... IT IS STORED IN FAT, FROM WHICH IT IS SLOWLY RELEASED TO GIVE SUSTAINED ACTION.

ESTROGENIC ACTIVITY HAS BEEN FOUND IN ADIPOSE TISSUE UP TO MONTH AFTER CESSATION OF THERAPY.

Cellular LocationsCytoplasm

用途と製造

UsesMEDICATION
Methods of ManufacturingPREPD BY REACTING TRI-P-ANISYLETHYLENE OR TRI-P-ANISYLETHANOL WITH CL IN INERT SOLVENT: BASFORD & ICI BRITISH PATENT 561,508 (1944).
Formulations/PreparationsCHLOROTRIANISENE, NF (TACE), IS LONG-ACTING ORAL PREPN... IT IS AVAIL IN 12-, 25-, & 72-MG CAPSULES & HAS ABOUT 1/8 ACTIVITY OF DIETHYLSTILBESTROL.

応用分野

使用Chlorotrianisene USP (TACE) is used to treat Androgen dependent carcinoma of the prostate.

一般的な説明Small white crystals or white powder. Softens at 226°F. Odorless.

上流・下流製品情報

上流原料

4'-メトキシアセトフェノングリニャール試薬スチレン , モノマーアニソールクロロアセチルクロリドAnisic acid